Research
Hormonal
Bariatric surgeries, specifically Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), reduce fasting plasma LEAP2 levels in humans with obesity, correlating with weight loss and improved metabolic markers.
Bariatric surgeries like RYGB and VSG lower levels of the hormone LEAP2, which is typically high in obesity. This hormonal shift, along with weight loss, may help maintain the weight loss by altering hunger signaling. This suggests that surgery works partly by resetting hormonal balances.
GoodSupportsHIGH confidence
Fasted plasma LEAP2 was significantly lower at 2 years after RYGB... Plasma LEAP2... was significantly lower after VSG surgery when compared with before VSG surgery.
Why this rating
Human clinical data with pre- and post-intervention measurements.
Source
LEAP2 changes with body mass and food intake in humans and mice
Bharath K. Mani et al. · Journal of Clinical Investigation · 2019
DOI 10.1172/jci125332
cohortCited 205×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- LEAP2 acts as a GHSR antagonist that hyperpolarizes arcuate NPY neurons and prevents acyl-ghrelin from activating them, thereby blunting ghrelin's orexigenic effects.Strong
- Plasma LEAP2 levels increase with higher body mass, obesity, and postprandial states in humans and mice, acting as an endogenous antagonist to acyl-ghrelin to limit food intake and blood glucose elevation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →